Dr. Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, Dr. Lanling Zou, Chief of Translational Sciences and Dr. Ping Chen, Director of China Office, Nation Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) visited TenNor Therapeutics on May 22, 2015. Dr. Zhenkun Ma, Founder and CEO, provided an update on TenNor’s antibacterial R&D program. Guests from NIH expressed great interests in TenNor’s novel dual-action molecule platform and a series of dual-action compounds in its current development pipeline. Dr. Dennis Dixon and Dr. Lanling Zou presented their work titled Antibacterial Resistance: Needs and Opportunities and Resources for the Microbiology & Infectious Diseases Research Community respectively. The parties agreed to further discuss collaborative opportunities in antibacterial area and reached broad consensus in directions for potential collaboration.

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com